Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_assertion type Assertion NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_head.
- NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_assertion description "[Clinicopathologic data showed that decreased TCF4 expression occurred significantly more frequently in intestinal-type (22/37, 59%) than in diffuse-type (7/37, 19%) gastric cancers (P = 0.0004) and likewise more frequently in early (12/18, 67%) than in advanced (17/59, 29%) gastric cancers (P = 0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_provenance.
- NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_assertion evidence source_evidence_literature NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_provenance.
- NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_assertion SIO_000772 18635522 NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_provenance.
- NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_assertion wasDerivedFrom befree-20140225 NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_provenance.
- NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_assertion wasGeneratedBy ECO_0000203 NP203938.RAV41Eb2AhtYngXvT4xZ9l3dVZ7x6nHOoaSSH35epAXkc130_provenance.